Deutsche Bank AG set a $24.00 price target on AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in a research note published on Friday. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.
AMAG has been the subject of a number of other research reports. Jefferies Group LLC set a $40.00 price objective on shares of AMAG Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, April 20th. Cantor Fitzgerald restated a hold rating and set a $23.00 price objective on shares of AMAG Pharmaceuticals in a research report on Tuesday, May 2nd. TheStreet downgraded shares of AMAG Pharmaceuticals from a c rating to a d+ rating in a research report on Friday, May 5th. Barclays PLC restated a hold rating and set a $25.00 price objective on shares of AMAG Pharmaceuticals in a research report on Friday, May 5th. Finally, ValuEngine downgraded shares of AMAG Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, May 11th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $28.45.
AMAG Pharmaceuticals (AMAG) traded up 1.432% on Friday, reaching $19.475. 362,513 shares of the company’s stock were exchanged. The company’s market capitalization is $682.50 million. AMAG Pharmaceuticals has a 1-year low of $16.00 and a 1-year high of $36.83. The firm has a 50-day moving average price of $18.02 and a 200-day moving average price of $23.21.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks’ consensus estimate of $0.09 by $1.15. The firm had revenue of $139.47 million for the quarter, compared to analysts’ expectations of $150.32 million. AMAG Pharmaceuticals had a positive return on equity of 1.69% and a negative net margin of 5.61%. The firm’s quarterly revenue was up 27.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.22) EPS. Equities research analysts expect that AMAG Pharmaceuticals will post $5.12 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.wkrb13.com/markets/2285979/amag-pharmaceuticals-inc-amag-given-a-24-00-price-target-at-deutsche-bank-ag.html.
In other news, SVP Julie Krop sold 1,891 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $24.45, for a total value of $46,234.95. Following the completion of the transaction, the senior vice president now owns 36,777 shares in the company, valued at approximately $899,197.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.80% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Advisors Asset Management Inc. increased its position in shares of AMAG Pharmaceuticals by 259.9% in the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock worth $156,000 after buying an additional 5,005 shares in the last quarter. Mason Street Advisors LLC increased its position in shares of AMAG Pharmaceuticals by 7.4% in the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $181,000 after buying an additional 554 shares in the last quarter. Sei Investments Co. increased its position in AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock valued at $188,000 after buying an additional 54 shares during the period. Affinity Investment Advisors LLC increased its position in AMAG Pharmaceuticals by 51.4% in the first quarter. Affinity Investment Advisors LLC now owns 9,747 shares of the specialty pharmaceutical company’s stock valued at $220,000 after buying an additional 3,310 shares during the period. Finally, Baird Financial Group Inc. acquired a new position in AMAG Pharmaceuticals during the first quarter valued at $220,000.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285979/amag-pharmaceuticals-inc-amag-given-a-24-00-price-target-at-deutsche-bank-ag.html
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.